Department of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Breast Cancer Res Treat. 2010 Oct;123(3):757-65. doi: 10.1007/s10549-009-0675-8. Epub 2009 Dec 22.
Multiple different biologically and clinically relevant genes are often amplified in invasive breast cancer, including HER2, ESR1, CCND1, and MYC. So far, little is known about their role in tumor progression. To investigate their significance for tumor invasion, we compared pure ductal carcinoma in situ (DCIS) and DCIS associated with invasive cancer with regard to the amplification of these genes. Fluorescence in situ hybridization (FISH) was performed on a tissue microarray containing samples from 130 pure DCIS and 159 DCIS associated with invasive breast cancer. Of the latter patients, we analyzed the intraductal and invasive components separately. In addition, lymph node metastases of 23 patients with invasive carcinoma were included. Amplification rates of pure DCIS and DCIS associated with invasive cancer did not differ significantly (pure DCIS vs. DCIS associated with invasive cancer: HER2 22.7 vs. 24.2%, ESR1 19.0 vs. 24.1%, CCND1 10.0 vs. 14.8%, MYC 11.8 vs. 6.5%; P > 0.05). Furthermore, we observed a high concordance of the amplification status for all genes if in situ and invasive carcinoma of individual patients were compared. This applied also to the corresponding lymph node metastases. Our results indicate no significant differences between the gene amplification status of DCIS and invasive breast cancer concerning HER2, ESR1, CCND1, and MYC. Therefore, our data suggest an early role of all analyzed gene amplifications in breast cancer development but not in the initiation of invasive tumor growth.
在浸润性乳腺癌中，经常会扩增多种具有生物学和临床意义的基因，包括 HER2、ESR1、CCND1 和 MYC。迄今为止，人们对这些基因在肿瘤进展中的作用知之甚少。为了研究它们在肿瘤侵袭中的意义，我们比较了纯导管原位癌（DCIS）和伴有浸润性癌的 DCIS 中这些基因的扩增情况。我们对包含 130 例纯 DCIS 和 159 例伴有浸润性乳腺癌的 DCIS 组织微阵列进行了荧光原位杂交（FISH）检测。在后者的患者中，我们分别分析了导管内和浸润性成分。此外，还包括 23 例浸润性癌患者的淋巴结转移。纯 DCIS 和伴有浸润性癌的 DCIS 的扩增率无显著差异（纯 DCIS 与伴有浸润性癌的 DCIS：HER2 22.7% vs. 24.2%，ESR1 19.0% vs. 24.1%，CCND1 10.0% vs. 14.8%，MYC 11.8% vs. 6.5%；P > 0.05）。此外，如果比较单个患者的原位癌和浸润性癌，我们观察到所有基因的扩增状态具有高度一致性。这也适用于相应的淋巴结转移。我们的结果表明，在 HER2、ESR1、CCND1 和 MYC 方面，DCIS 和浸润性乳腺癌的基因扩增状态没有显著差异。因此，我们的数据表明所有分析的基因扩增在乳腺癌发展中具有早期作用，但不是浸润性肿瘤生长的起始作用。
